Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial.

Kantartzis K, Fritsche L, Bombrich M, Machann J, Schick F, Staiger H, Kunz I, Schoop R, Lehn-Stefan A, Heni M, Peter A, Fritsche A, Häring HU, Stefan N.

Diabetes Obes Metab. 2018 Jul;20(7):1793-1797. doi: 10.1111/dom.13268. Epub 2018 Mar 22.

PMID:
29484808
2.

Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol.

Wicklow B, Wittmeier K, T' Jong GW, McGavock J, Robert M, Duhamel T, Dolinsky VW.

Biochem Cell Biol. 2015 Oct;93(5):522-30. doi: 10.1139/bcb-2014-0136. Epub 2015 Jul 10.

PMID:
26305052
3.

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.

Faghihzadeh F, Adibi P, Hekmatdoost A.

Br J Nutr. 2015 Sep 14;114(5):796-803. doi: 10.1017/S0007114515002433. Epub 2015 Aug 3.

PMID:
26234526
4.

Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris: A double-blind placebo-controlled randomized clinical trial.

Ebrahimi-Mameghani M, Sadeghi Z, Abbasalizad Farhangi M, Vaghef-Mehrabany E, Aliashrafi S.

Clin Nutr. 2017 Aug;36(4):1001-1006. doi: 10.1016/j.clnu.2016.07.004. Epub 2016 Jul 19.

PMID:
27475283
5.

Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial.

Most J, Timmers S, Warnke I, Jocken JW, van Boekschoten M, de Groot P, Bendik I, Schrauwen P, Goossens GH, Blaak EE.

Am J Clin Nutr. 2016 Jul;104(1):215-27. doi: 10.3945/ajcn.115.122937. Epub 2016 May 18.

PMID:
27194304
6.

Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.

Frøssing S, Nylander M, Chabanova E, Frystyk J, Holst JJ, Kistorp C, Skouby SO, Faber J.

Diabetes Obes Metab. 2018 Jan;20(1):215-218. doi: 10.1111/dom.13053. Epub 2017 Aug 11.

PMID:
28681988
7.

Resveratrol does not benefit patients with nonalcoholic fatty liver disease.

Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M, Coombes JS, Thomas GP, Cowin GJ, Kirkpatrick CM, Prins JB, Hickman IJ.

Clin Gastroenterol Hepatol. 2014 Dec;12(12):2092-103.e1-6. doi: 10.1016/j.cgh.2014.02.024. Epub 2014 Feb 25.

PMID:
24582567
8.

No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

Barchetta I, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, Saulle R, Perri L, Morini S, Tiberti C, Bertoccini L, Cimini FA, Panimolle F, Catalano C, Baroni MG, Cavallo MG.

BMC Med. 2016 Jun 29;14:92. doi: 10.1186/s12916-016-0638-y.

9.

No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial.

Kjær TN, Ornstrup MJ, Poulsen MM, Stødkilde-Jørgensen H, Jessen N, Jørgensen JOL, Richelsen B, Pedersen SB.

J Clin Endocrinol Metab. 2017 May 1;102(5):1642-1651. doi: 10.1210/jc.2016-2160.

PMID:
28182820
10.

Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.

Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, Shu F, Gao Y, Yuan L, Zhang Q, Mi M.

Dig Liver Dis. 2015 Mar;47(3):226-32. doi: 10.1016/j.dld.2014.11.015. Epub 2014 Dec 16.

PMID:
25577300
11.

A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease.

Pacifico L, Bonci E, Di Martino M, Versacci P, Andreoli G, Silvestri LM, Chiesa C.

Nutr Metab Cardiovasc Dis. 2015 Aug;25(8):734-41. doi: 10.1016/j.numecd.2015.04.003. Epub 2015 Apr 25.

PMID:
26026214
12.

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.

Stefan N, Ramsauer M, Jordan P, Nowotny B, Kantartzis K, Machann J, Hwang JH, Nowotny P, Kahl S, Harreiter J, Hornemann S, Sanyal AJ, Stewart PM, Pfeiffer AF, Kautzky-Willer A, Roden M, Häring HU, Fürst-Recktenwald S.

Lancet Diabetes Endocrinol. 2014 May;2(5):406-16. doi: 10.1016/S2213-8587(13)70170-0. Epub 2014 Feb 17.

PMID:
24795254
14.

Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.

Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A.

Nutr Res. 2014 Oct;34(10):837-43. doi: 10.1016/j.nutres.2014.09.005. Epub 2014 Sep 23.

PMID:
25311610
15.

Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.

Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjær Poulsen M, Stødkilde-Jørgensen H, Møller HJ, Jessen N, Thorsen K, Kristina Hellberg Y, Bønløkke Pedersen S, Grønbæk H.

Scand J Gastroenterol. 2016;51(4):456-64. doi: 10.3109/00365521.2015.1107620.

PMID:
26784973
16.

High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition.

Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stødkilde-Jørgensen H, Møller N, Jessen N, Pedersen SB, Jørgensen JO.

Diabetes. 2013 Apr;62(4):1186-95. doi: 10.2337/db12-0975. Epub 2012 Nov 28.

17.

Regression of Non-Alcoholic Fatty Liver by Vitamin D Supplement: A Double-Blind Randomized Controlled Clinical Trial.

Lorvand Amiri H, Agah S, Mousavi SN, Hosseini AF, Shidfar F.

Arch Iran Med. 2016 Sep;19(9):631-8. doi: 0161909/AIM.006.

18.

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.

Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, Richards L, Salotti J, Bhatt A, Hooker J, Haufe W, Hooker C, Brenner DA, Sirlin CB, Loomba R.

J Hepatol. 2016 Aug;65(2):369-76. doi: 10.1016/j.jhep.2016.04.021. Epub 2016 May 2.

19.

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, Loomba R.

Lancet. 2018 Mar 24;391(10126):1174-1185. doi: 10.1016/S0140-6736(18)30474-4. Epub 2018 Mar 5. Erratum in: Lancet. 2018 Mar 24;391(10126):e16.

PMID:
29519502
20.

Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial.

Lorvand Amiri H, Agah S, Tolouei Azar J, Hosseini S, Shidfar F, Mousavi SN.

Clin Nutr. 2017 Dec;36(6):1490-1497. doi: 10.1016/j.clnu.2016.09.020. Epub 2016 Sep 28.

PMID:
27720403

Supplemental Content

Support Center